15. The method of the administration of drugs with binding affinity for plasma protein according to Claim 14, wherein the second drug has binding affinity to the same binding sites on plasma protein to which the first drug has binding affinity.

16. The method of the administration of drug with binding affinity for plasma protein according to Claim 14, wherein the first drug is a radiodiagnostic drug for in vivo use or a radiotherapeutic drug for in vivo use.

17. The method of the administration of drugs with binding affinity for plasma protein according to Claim 15, wherein the first drug is a raiodiagnostic drug for in vivo use or the radiotherapeutic drug for in vivo use.

18. The method of the administration of drugs with binding affinity for plasma protein according to Claim 16 or 17, wherein the radiodiagnostic drug for in vivo use or the radiotherapeutic drug for in vivo use is radiolabeled with one nuclide selected from the group consisting of 11-carbon (^{11}C), 15-oxygen (^{15}O), 18-fluorine (^{18}F), 32-phosphorus (^{32}P), 59-iron (^{59}Fe), 67-copper (^{67}Cu), 67-gallium (^{67}Ga), 81m-krypton (^{81}Kr), 81-rubidium (^{81}Rb), 89-strontium (^{89}Sr), 90-yttrium (^{90}Y), 99m-technetium (^{99m}Tc), 111-indium (^{111}In), 123-iodine (^{123}I), 125-iodine (^{125}I), 131-iodine (^{131}I), 133-xenon (^{133}Xe), 117m-tin (^{117m}Sn), 153-samarium (^{153}Sm), 186-rhenium (^{186}Re), 188-rhenium (^{188}Re), 201-thallium (^{201}T1), 212-bismuth (^{212}Bi), 213-bismuth (^{213}Bi) and 211-astatine (^{211}At).

19. The method of the administration of drugs with binding affinity for plasma protein according to Claim 16 or 17, wherein the first drug has one group labeled with nuclide and the group is selected from the group consisting of bisaminothiol or its derivatives, monaminomonoamidobisthiol or its derivatives, bisamidobisthiol or its derivatives, mercaptoacetylglycylglycylglycine or its derivatives, hexamethylpropyleneamineoxime or its

derivatives, ethylenebis [bis(2-ethoxyethyl) phosphine] or its derivatives, 2,3-dimercaptosuccinic acid or its derivatives, ethylenecysteine dimer derivatives, methoxyisobutylisonitrile derivatives, polyamine derivatives, pyriodoxylydeneaminate derivatives, methylene diphosphonate, hydroxymethylene diphosphonate derivatives, β-methyl-ω-phenylpentadecanoic acid or its derivatives, N-isopropylamphetamine, hippuric acid and benzylguanidine and tropane derivatives.

20. The method of the administration of drugs with binding affinity for plasma protein according to any one of claims 14 to 17, wherein the single or plural second drug is selected from the group consisting of bucolome, cefazolin, etoposide, phenylbutazone, aspirine, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil and disopyramide.

21. A pharmaceutical preparation for regulating binding affinity of a first drug for plasma protein, which comprises a first drug with binding affinity for plasma protein and a single or plural second drug with binding affinity for the same plasma protein, for which the first drug has binding affinity.

22. The pharmaceutical preparation according to Claim 21, wherein each of the first drug and the second drug is separately filled in a container, and prepared as a kit form for supply.

23. The pharmaceutical preparation according to Claim 21, wherein the second drug has binding affinity to the same binding sites on the plasma protein, to which the first drug has binding affinity.

24. The pharmaceutical preparation according to Claim 22, wherein the second drug has binding affinity to the same binding sites on the plasma protein, to which the first drug has binding affinity.

25. The pharmaceutical preparation according to any one of Claims 21 to 24, wherein the first drug is a radiodiagnostic drug for in vivo use or a radiotherapeutic drug for in vivo use.

26. The pharmaceutical preparation according to Claim 25, wherein the radiodiagnostic drug for in vivo use or the radiotherapeutic drug for in vivo use is radiolabeled with one nuclide selected from the group consisting of 11-carbon (^{11}C), 15-oxygen (^{15}O), 18-fluorine (^{18}F), 32-phosphorus (^{32}P), 59-iron (^{59}Fe), 67-copper (^{67}Cu), 67-gallium (^{67}Ga), 81m-krypton (^{81m}Kr), 81-rubidium (^{81}Rb), 89-strontium (^{89}Sr), 90-yttrium (^{90}Y), 99m-technetium (^{99m}Tc), 111-indium (^{111}In), 123-iodine (^{123}I), 125-iodine (^{125}I), 131-iodine (^{131}I), 133-xenon (^{133}Xe), 117m-tin (^{117m}Sn), 153-samarium (^{153}Sm), 186-rhenium (^{186}Re), 188-rhenium (^{188}Re), 201-thallium (^{201}Tl), 212-bismuth (^{212}Bi), 213-bismuth (^{213}Bi) and 211-astatine (^{211}At).

27. The pharmaceutical preparation according to Claim 25, wherein the first drug has one group labeled with nuclide and the group is selected from the group consisting of bisaminothiol or its derivatives, monoaminomonoamidobisthiol or its derviaties, bisamidobisthiol or its derivatives, mercaptoacetylglycylglycylglycine or its derivatives, hexamethylpropyleneamineoxime or its derivatives, ethylenebis [bis (2-ethoxyethyl) phosphine] or its derivatives, 2,3-dimercaptosuccinic acid or its derivatives, ethylenecysteine dimer derivatives, methoxyisobutylisonitrile derivatives, polyamine derivatives, pyridoxylydeneaminate derivatives, methylene diphosphonate, hydroxymethylene diphosphonate derivatives, β-methyl-ω-phenylpentadecanoic acid or its derivatives, N-isopropylamphetamine, hippuric acid, benzylguanidine and tropane derivatives.

28. The pharmaceutical preparation according to any one of Claims 21 to 24, wherein the single or plural second drug is selected from the group consisting of bucolome, cefazolin, etoposide, phenylbutazone, aspirine, salicylic acid, ceftriaxone, sulfamethizole, valproic acid,

nabumetone, 6-methoxy-2-naphthylacetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil and disopyramide.

29. The pharmaceutical preparation according to Claim 25, wherein the single or plural second drug is selected from the group consisting of bucolome, cefazoline, etoposide, phenylbutazone, aspirine, salicylic acid, ceftriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-2-naphthylacetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil and disopyramide.

REMARKS

Entry and consideration of this Amendment is respectfully requested.

Respectfully submitted,

Sheldon I. Landsman
Registration No. 25,430

SUGHRUE MION, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3213
Telephone: (202) 293-7060
Facsimile: (202) 293-7860
SIL/slb
Date: December 21, 2001